Autoimmune Disease Treatment Market 2022 Revenue, Growth Rate, Sales, and Forecast to 2030


The global Autoimmune Disease Treatment Market is projected to reach USD 2,104 Million by 2030 at 6.90% CAGR during the forecast period 2022-2030.

.

The global Autoimmune Disease Treatment Market  is projected to reach USD 2,104 Million by 2030 at 6.90% CAGR during the forecast period 2022-2030. The global autoimmune disease treatment market is mainly driven by the growing prevalence of autoimmune diseases, the growing awareness about autoimmune disease treatment, and the growing development of a number of effective treatments for autoimmune diseases based on modern medical processes such as genomics.

Autoimmune diseases are diseases caused by the immune system mistaking the body’s own tissue for foreign tissues and attacking it. This can happen due to a number of complications within the immune system and can have disastrous consequences on the health of the individual. Some of the most widely prevalent autoimmune diseases include rheumatoid arthritis, lupus, and multiple sclerosis. Growing awareness about autoimmune diseases and their treatment is likely to be a major driver for the global autoimmune disease treatment market over the forecast period. While autoimmune diseases have always been present among human populations, their sporadic appearance and lack of infectiousness made them relatively minor subjects of study compared to other, more imminent threats. The growing prevalence of autoimmune diseases in modern times has led to growing awareness about the disease and is likely to remain the key driver for the autoimmune disease treatment market over the forecast period.

Growing development of effective treatments for a number of autoimmune diseases is likely to be a major driver for the global autoimmune disease treatment market over the forecast period. Autoimmune diseases can be hard to treat effectively, as treating them effectively means shutting down or slowing down the operations of the body’s immune system. While this may be an effective way of combating autoimmune diseases, this can also leave the body vulnerable to other infections and diseases that can make the most of the body’s temporary weakness. The use of genetic components in treating autoimmune diseases is a new aspect gained by the autoimmune disease treatment market in the last few years and is likely to remain a key part of the market over the forecast period due to the increasing awareness about its effectiveness and safety.

Competitive Analysis:

Leading players in the global autoimmune disease treatment market include Abbott Laboratories, Genentech Inc., Biogen Idec Inc., Chugai Pharmaceutical Co. Ltd., Elan Corporation plc, F. Hoffman-La Roche AG, HYCOR Biomedical, Merck Co. Inc., Squibb Company, Thermo Fisher Scientific, Siemens, Johnson Johnson Inc., GlaxoSmithKline plc, Eli Lilly and Company, Danaher, Bio-Rad, Bayer Schering Pharma AG, and Amgen Inc.

Industry Updates:

Researchers at the University of Virginia School of Medicine, working in collaboration with Inova Health, discovered in February 2019 that deleting a gene called ELMO1 reduces the severity of arthritis in mice. Such discoveries could prove crucial for the global autoimmune disease treatment market over the forecast period, as the genetic background of autoimmune diseases is likely to take on an important role due to the growing understanding and awareness about genetics and its application in disease treatment.

Segmentation:

The global autoimmune disease treatment market is segmented on the basis of disease type, diagnosis, therapeutic products, distribution channels, and region.

On the basis of the disease type, the market is classified into localized diseases and systemic diseases. The localized segment is further classified into multiple sclerosis, inflammatory bowel disease, diabetes, and others, whereas the systemic segment is segmented into rheumatoid arthritis, psoriasis, lupus, and others.

On the basis of diagnosis, the autoimmune disease treatment market is classified as ELISA, dot blot, line blot, agglutination, double immune diffusion, western blotting, multiplex immunoassay, and others.

On the basis of the therapeutic product, the autoimmune disease treatment market is segmented into drugs and therapeutic monitoring equipment. The drugs segment is further segmented into biologics, immunosuppressants, anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatory drugs.

On the basis of the distribution channel, the autoimmune disease treatment market is segmented into hospitals clinics, diagnostic centers, drug stores, pharmacies, and others.

Regional Analysis:

The Americas are likely to remain the leading revenue generator in the global autoimmune disease treatment market over the forecast period due to the growing economic burden of autoimmune diseases and the rapid growth of the healthcare sector to equip itself with modern methodologies to deal with autoimmune diseases. Europe holds the second largest share in the global autoimmune disease treatment market and is likely to remain a sizeable contender over the forecast period due to the growing government support to advances in the healthcare sector.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Market Research Future

Market Research Future

Office No. 524/528, Amanora Chambers

Magarpatta Road, Hadapsar

Pune – 411028

Maharashtra, India

+1 646 845 9312

 

 

Comments